Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05456503 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Eligibility criteria expanded, about 32 words Study description revised Show 1 more changeShow less
    • Study description revised
  2. Interventions: FPI-2620 (Drug) to [18F]-PI-2620 (Drug) Eligibility criteria expanded, about 55 words · Study description revised · Study title revisedv9 Show 3 more changesShow less
    • Eligibility criteria expanded, about 55 words
    • Study description revised
    • Study title revised

    See this version in full on ClinicalTrials.gov ↗

  3. Eligibility criteria shortened, about 86 words Study description expanded, about 84 wordsv8 Show 1 more changeShow less
    • Study description expanded, about 84 words

    See this version in full on ClinicalTrials.gov ↗

  4. Primary and study completion dates: Aug 2026 to Aug 2028 Study description expanded, about 112 wordsv7 Show 1 more changeShow less
    • Study description expanded, about 112 words

    See this version in full on ClinicalTrials.gov ↗

  5. Site contact updatedv6
Show 4 earlier versionsHide 4 earlier versions
  1. Enrollment target: 54 to 72 Eligibility criteria expanded, about 106 words · Study description shortened, about 63 words · Site contact updated · 1 morev5 Show 4 more changesShow less
    • Eligibility criteria expanded, about 106 words
    • Study description shortened, about 63 words
    • Site contact updated
    • Study arms: 6 to 7

    See this version in full on ClinicalTrials.gov ↗

  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Sep 2022 to Sep 19, 2022 · Site details revisedv4 Show 2 more changesShow less
    • Start date changed from estimate of Sep 2022 to Sep 19, 2022
    • Site details revised
  3. Start date: Aug 2022 to Sep 2022 Interventions: [18F]PI-2620 (Drug) to FPI-2620 (Drug)v3 Show 1 more changeShow less
    • Interventions: [18F]PI-2620 (Drug) to FPI-2620 (Drug)
  4. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The investigators will compare \[18F\]-PI-2620 tau PET scans from patients with frontotemporal lobar degeneration (FTLD), patients with non-amnestic presentations of Alzheimer's disease (naAD), and demographically matched cognitively normal subjects.
Trial Details
NCT Number NCT05456503
Lead Sponsor University of Pennsylvania
Collaborators: National Institutes of Health (NIH)
Conditions Frontotemporal Lobar Degeneration, Alzheimer Disease, Cognitively Normal
Enrollment 72 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov